RxDoctor Payments Data

Laura Krol

Nurse Practitioner · Milwaukee, WINPI 1467948315

Payments from drug & device makers

$4,116in general payments, 2019–2025

Across 165 payments — averaging $24.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$932
  • Johnson & Johnson$470
  • Pfizer$390
  • AbbVie$265
  • Procept Biorobotics Corporation$230
  • Urogen Pharma, Inc.$222
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$3,82793%
  • Education$2897%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,116 in reported general payments places this provider in the 95th percentile of 3,478 nurse practitioner providers in Wisconsin.

See all nurse practitioner providers in Wisconsin

Medicare billing

Part B allowed, 2024
$24,060
Medicare patients
168
Services billed
1,922

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron110$100,745
GemtesaVibegron78$61,506
ElmironPentosan Polysulfate Sodium24$15,418
Methenamine Hippurate78$7,399
Tamsulosin Hcl318$3,277
Finasteride154$1,948
Alfuzosin Hcl ErAlfuzosin Hcl77$1,670
Solifenacin Succinate19$1,223
Oxybutynin Chloride ErOxybutynin Chloride78$1,085
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst75$1,033
Dutasteride24$691
Cephalexin82$627
Estradiol12$626
Trimethoprim16$422
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim72$391

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$932$100,745110 claims
Sumitomo Pharma America, Inc.Gemtesa$156$61,50678 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,478 nurse practitioner providers in Wisconsin.

Other nurse practitioner in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →